Infliximab News and Research

RSS
Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.
People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis – new treatments wanted

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Study identifies genetic marker which could personalize treatment for Crohn's disease

Study identifies genetic marker which could personalize treatment for Crohn's disease

Common genetic variant explains why immunotherapy often fails in Crohn's disease

Common genetic variant explains why immunotherapy often fails in Crohn's disease

New therapeutic target for rheumatoid arthritis and type 2 diabetes

New therapeutic target for rheumatoid arthritis and type 2 diabetes

Research suggests new way to improve the efficacy of arthritis drug

Research suggests new way to improve the efficacy of arthritis drug

Study: Biologic therapy did not reduce IBD-related hospitalizations and surgeries

Study: Biologic therapy did not reduce IBD-related hospitalizations and surgeries

Dermcidin in human sweat may contribute to pathogenesis of hidradenitis suppurativa

Dermcidin in human sweat may contribute to pathogenesis of hidradenitis suppurativa

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Celltrion Healthcare advocates early introduction of biologics for patients to improve clinical outcomes

Celltrion Healthcare advocates early introduction of biologics for patients to improve clinical outcomes

Genetic test to predict IBD severity in children

Genetic test to predict IBD severity in children

Study shows efficacy of biologics for mucosal healing in Crohn's disease and ulcerative colitis

Study shows efficacy of biologics for mucosal healing in Crohn's disease and ulcerative colitis

New, low-cost biosimilar for IBD therapy shows efficacy and safety

New, low-cost biosimilar for IBD therapy shows efficacy and safety

Researchers receive $2 million grant from PCORI to study effective treatment for children with KD

Researchers receive $2 million grant from PCORI to study effective treatment for children with KD

Penn scientists develop combined medical and surgical care plan for managing Crohn's disease

Penn scientists develop combined medical and surgical care plan for managing Crohn's disease

Generic biologic drugs appear to be as effective as brand-name versions

Generic biologic drugs appear to be as effective as brand-name versions

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.